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Abstract: The search for effective drugs against cisplatin-resistant tumors resulted in a large number of
organometallic compounds that are evaluated for their antiproliferative activity. Among the most promising
candidates are bent metallocenes based on various transition metal ions and ligands. The elucidation of
structural features and the characterization of the interaction of a drug candidate with its target require accurate
and sensitive analytical tools. Tandem mass spectrometry is applied to the investigation of the adduct sites and
binding patterns of metallodrugs bound to single-stranded oligonucleotides and higher-order nucleic acids.
Results reveal the binding specificities of the different metallodrugs and demonstrate the influence they exert on
the dissociation pathways of the adducts in the gas-phase.
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Introduction
Research in the life sciences has
been strongly accelerated over the
past two decades by the availability of
mass spectrometry-based techniques
for the analysis of peptide, protein, and
lipid biomarkers, as well as drugs and
their metabolites. Owing to its high
selectivity and sensitivity, tandem mass
spectrometry has evolved into one of the
most powerful tools for the elucidation
of molecular structures, the sequencing
of biopolymers, and the comprehensive
quantitation of organic compounds in
complex matrices. The characterization
of complex mixtures can be approached
by a combination of chromatographic
separation, soft ionization, and high-
resolution mass analysis. Furthermore,
the ability of tandem mass spectrometry
(MS/MS) to select and activate precursor
ions in the gas-phase makes the method
inherently well suited for the analysis of
heterogeneous samples. In contrast to the
rapid expansion of mass spectrometry-
based proteomics and diagnostics, the
characterization of nucleic acids remains
a niche application. Nevertheless, the
identification and quantitation of nucleic
acidmodifications,thesequencingofhighly
modified therapeutic oligonucleotides,
and the elucidation of drug-nucleic acid
interactions represent key applications that
benefit from the strengths of tandem mass
spectrometry.
Sequencing of Nucleic Acids by
Tandem Mass Spectrometry
When seen from a distance, the tandem
mass spectrometric sequencing of any
biopolymer might essentially follow the
same principle. Analyte ions of interest are
isolated in the gas-phase and their internal
energy is increased, commonly by collision
with an inert gas in a process referred to as
collision-induced dissociation (CID). As
a result of this activation, covalent bonds
are cleaved and one or more series of
backbone fragments are generated, which
provide the desired sequence information.
However, due to unique structural
features, peptides and oligonucleotides
exhibit completely different gas-phase
behaviors. While peptides predominantly
dissociate by scission of the amide
bond that links two adjoining amino
acids, the structure dependence of
oligonucleotide fragmentation is much
more pronounced and more often than not,
several dissociation events coincide. The
backbone cleavage of deoxyribonucleic
acids (DNA) is always accompanied by the
loss of a nucleobase, as this represents the
initial step of the dissociation mechanism
eventually resulting in the cleavage of
the 3'-C-O bond and the formation of the
so-called (a-B)- and w-fragment ions
(Fig. 1).
[1]
In contrast, the cleavage of the
5'-P-O phosphoester bond in ribonucleic
acids (RNA) is independent of nucleobase
loss and results in the c- and y-fragment
ions.
[2,3]
Oligonucleotides administered
for therapeutic purposes (e.g. for antisense
applications) commonly comprise struc-
tural modifications of the backbone, the
sugar moiety, or the nucleobases in order
to improve their biostability and to tailor
their interaction with the complementary
nucleic acid targets. Such modifications
influence the dissociation pathways of the
oligonucleotides and, consequently, affect
the resulting product ion spectra.
[4–6]
In
any case, charge-induced nucleobase loss,
the occurrence of internal fragments due
to secondary dissociation events, and the
presence of ubiquitous alkali ion adducts
further complicate the mass spectral data.
Software-supported Spectra
Interpretation
The great diversity of possible dis-
sociation products turns the elucidation
of nucleotide sequences and their
structural modifications into a very time-
consuming and error-prone process.
Spectra interpretation is greatly facilitated
by the software tool OMA & OPA
(oligonucleotide mass assembler &
oligonucleotide peak analyzer) developed
in our department.
[7]
The Java-based
software calculates the masses of all
theoretically possible fragments of a given
single-stranded oligonucleotide or duplex
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metallocenes comprising functionalized
cyclopentadienyl ligands, such as titano-
cene Y, which exhibits methoxybenzyl-
substituted ligands, moved into the focus
of anticancer drug development.
[16]
In contrast to planar platinum-based
drugs, the binding preferences and binding
patterns of bentmetallocenes to single- and
double-strandednucleicacidshavenotbeen
elucidated in detail yet. Sincemetallodrugs
do not only target a single,well-defined site
in nucleic acids, heterogeneous mixtures
of adducts are generated upon incubation
with oligonucleotides, which renders
their characterization difficult. Despite
the increased sample complexity, adducts
exhibiting different stoichiometries can
easily be separated in the gas-phase and
selected as precursors for tandem mass
spectrometric analysis.
Initial experiments on simple model
systems revealed very diverse target
specificities and binding patterns of
metallocenes based on different transition
metal ions. The binding of metallocenes
to deoxydinucleoside monophosphates
was found to follow the Pearson hard-
soft acid-base (HSAB) concept. Metal
ions with small radii and high charge (e.g.
Ti
4+
) are classified as hard Lewis acids that
preferentially bind to hard Lewis bases,
such as the oxygen atoms of phosphate
groups. This preference is reflected by the
product ion spectra of the adducts formed
between titanocene and the dinucleoside
monophosphates d(CpT) and d(TpC). In
Fig. 2a, the base peak (m/z 499) refers to
the [w
1
+Cp
2
Ti]
+
fragment ion, which is
generated by the scission of the 3'-C-O
bond. The peak at m/z 355 corresponds
to [w
1
+Cp
2
Ti-TH-H
2
O]
+
(structure shown
in Fig. 2), a secondary fragment ion
that has lost its nucleobase and a water
molecule. The presence of this secondary
fragment ion points to a strong interaction
of titanium with the phosphate group.
Due to the lack of a second phosphate
moiety in dinucleoside monophosphates,
the nucleobase represents the alternative
binding site. Such binding was found
to be highly nucleobase specific with
a preferred binding to thymine. This is
evidenced by the [w
1
+Cp
2
Ti]
+
ion derived
from the d(CpT) adduct (Fig. 2a), while
[M+Cp
2
Ti-CH-H
2
O]
+
constitutes the main
dissociation product of the adduct with
reversed base order (Fig. 2b).
On the other hand, larger, more
polarizable metal ions (e.g. Mo
4+
or Pt
2+
)
constitute softer Lewis acids that target
soft bases, such as electron-rich nitrogen
atoms of the nucleobases. This preference
is evidenced by the highly abundant
peak of the [G+Cp
2
Mo]
+
fragment in the
product ion spectrum of the d(ApG)-
molybdenocene adduct (Fig. 2c). The
spectrum also reveals that the bond to the
teraction of drug candidates with their
cellular targets. Various analytical
techniques, including NMR, X-ray diff-
raction, and mass spectrometry, have
been applied for that purpose. The latter
can give rapid proof for the interaction
between metallodrugs and their nucleic
acid targets and provide information
about the stoichiometry of the complexes.
Examples thereof range from established
platinum-based anticancer drugs to
current metallodrug candidates based
on various transition metals.
[8–10]
Since adduct formation represents a
structural alteration that influences the
accessibility of dissociation channels,
the spectra resulting from tandem mass
spectrometric experiments reflect the
adduct sites and binding patterns. The
effect of adduct formation on the gas-phase
decomposition has been demonstrated for
cisplatin bound to single-stranded model
oligonucleotides
[5,11,12]
as well as higher-
order structures.
[13]
Platination, which
primarily occurs at GG andAG base pairs,
was found to weaken the N-glycosidic
bond and, consequently, to promote
backbone cleavage on the 3'-side of the
adduct, resulting in the corresponding
w-fragment ion.
Metallocene Adducts
Among the metallodrugs evaluated
for their antiproliferative potential
against cancer cells, bent metallocenes
gained increased attention already in the
1990s. Initial expectations on titanocene
dichloride (Cp
2
TiCl
2
) shattered due to a
lack of effectiveness against breast and
renal cell carcinomas and the candidate
was not pursued beyond phase II
clinical trials.
[14,15]
Nevertheless, bent
sequence and matches the complete mass
list with the product ion spectrum. User-
defined structural modification of the
input sequence as well as adducts with any
cation or anion can easily be implemented,
which makes the tool extremely helpful
for the characterization of nucleic acid-
metallodrug adducts. The OMA &
OPA software can be downloaded from
http://schuerch.dcb.unibe.ch/index.php/
research-projects/oma-opa-software.
Characterization of Nucleic Acid–
Metallodrug Interactions
Cisplatin Adducts
Cisplatin (cis-diamminedichloroplati-
num (ii)) has been a strong pillar of
anticancer chemotherapy for decades
and is still administered today, mostly in
combination with newer-generation cyto-
toxic agents. The highly reactive cisplatin
forms covalent intra- and interstrand
cross-links in the DNA double helix. The
thereby caused structural alterations, such
as local unwinding and the bending of the
double helix, interfere with replication
and transcription processes and thus are
responsible for the antiproliferative effect
of cisplatin. Though cisplatin is highly
effective against various types of tumors,
patientsoftensuffer fromsevere sideeffects
and the treatment may be unsuccessful due
to intrinsic or acquired resistance of cancer
cells against drug-inducedapoptosis.These
shortcomings encouraged the development
of novel metallodrugs based on platinum
and alternative transition metals.
The quest for effective and less toxic
anticancer drugs demands powerful ana-
lytical techniques to characterize the in-
400 140012001000800600
m/z
GG AGA ACG A C A CAT C
PHO
O
O
O
B
1
B
2
5'
3'
w
bx
cy
dz
a
a-B
O
O
w
4
2-
w
2
-
a
5
-B
2-
w
3
-
w
4
-
y
4
-
w
1
-
a
6
-B
2-
a
8
-B
2-
a
5
-B
-
a
4
-B
-
w
6
2-
IF
IF
IF
IF
M
5-
w
5
2-
w
8
3-
w
7
3-
w
9
3-
w
10
3-
w
11
4-
w
13
4-
w
14
5-
a
2
-B
-
a
7
-B
2-
a
9
-B
3-
a
10
-B
2-
a
11
-B
3-
a
12
-B
3-
a
13
-B
4-
a
14
-B
4-
Fig. 1. Product ion spectrum generated by collisional activation of a fivefold charged DNA
15mer. The nucleotide sequence is reflected by the DNA-typical (a-B)- and w-fragment ion series
produced by cleavage of the 3'-C-O bond. Alternative dissociation channels and secondary
fragmentation events give rise to additional ion series and internal fragment ions (IF).
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Alternative Ion Activation
Techniques
The various techniques used for ion
activation in the gas-phase do not only
differ in the amount of transferred energy,
but also in the time frame required for
the transfer of sufficient energy and
in the mechanisms responsible for the
dissociation of the precursor ions. The
considerable long time frame required
for low-energy collisional activation (up
to 100 ms) enables the redistribution of
the added internal energy over the many
degrees of freedom of the ions prior to
fragmentation. This results in an ergodic
dissociation behavior, slows down the
reaction rate of covalent bond cleavage in
large ions, and promotes the cleavage of
non-covalent interactions, thus, impeding
the investigation of higher-order structural
features.
Alternative activation techniques that
prevent energy randomization are applied
to overcome this drawback. Among them
are radical-based methods such as electron
capture dissociation (ECD) and electron
transfer dissociation (ETD). Transfer of
electrons to a precursor ion population
stored ina trapping instrument triggersodd-
electron dissociation channels that provide
sequence and structural information
orthogonal to the data obtained by CID.
The effect of various activation techniques
on the types of generated fragment ions has
been demonstrated for oligonucleotide–
cisplatin adducts.
[12]
ETD was found to
primarily result in charge reduction of the
precursor ions, but backbone fragments
couldbegeneratedbyadditional collisional
activation of the charge-reduced precursor
ions. The transfer of an electron to nucleic
acids is highly nucleobase-specific with
a high preference for abstraction by a
cytosine nucleobase.
[17,18]
Our recent ETD
experiments on metallocene-DNA adducts
of different charge states provided deeper
insight into the radical-driven dissociation.
Electron transfer to the doubly charged
hexamer adduct resulted in charge
reduction only. Interestingly, electron
transfer to the triply charged precursor
ion led to the doubly reduced adduct. The
first electron was transferred to the metal
center and the second one abstracted by
the cytosine nucleobase, where it induced
backbone cleavage (Fig. 3). The extent of
electron transfer to the adduct was found to
depend on the coordination center, which is
likely to affect the dissociationmechanism.
Elucidation of this mechanism represents
the initial step on the way to extracting
orthogonal structure information on
higher-order nucleic acid assemblies and
identifying the binding characteristics of
metallodrugs.
structures due to the cleavage of covalent
bonds in the oligonucleotide backbone
without disrupting all non-covalent in-
teractions between the nucleobases.
[13,18]
This observation was somewhat unex-
pected, because low-energy CID is con-
sidered as a slow-heating ergodic process,
which redistributes the added internal en-
ergy among the vibrational modes of the
precursor ion prior to fragmentation and,
therefore, was expected to result in the
disruption of the non-covalent nucleobase
interactions. In some cases, the detection
of adducted and unadducted fragment ions
allowed the localization of the adduct sites.
Nevertheless, experimental alternatives are
necessary when strand separation impedes
precise characterization of the binding pat-
tern.
guanine nucleobase is much stronger than
the interaction with the adjacent adenine,
as reflected by the low peak intensity of
[A+Cp
2
Mo]
+
.
Higher-order Nucleic Acids
as Drug Targets
Due to their important roles in cellular
processes, higher-order structures, such as
duplex- and quadruplex-DNA, represent
potential drug targets as well. Despite the
non-covalent binding characteristics of
these assemblies, they do not necessar-
ily separate upon electrospray ionization
and collisional activation. Experiments
on non-platinated and platinated quadru-
plexes revealed the formation of truncated
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Fig. 2. Product ion
spectra generated by
collisional activation
of the adducts of a)
d(CpT) and b) d(TpC)
with titanocene
and c) d(ApG) with
molybdenocene.
In the applied
nomenclature, G
corresponds to a
negatively charged
guanine, whereas GH
indicates a neutral
nucleobase.
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Conclusion
The combination of accurate mass
high-resolution mass spectrometry with
multiple ion activation techniques forms
a powerful toolkit for the investigation
of biomolecule-drug interactions. Among
the analytical techniques applied in the
life sciences, tandem mass spectrometry
excels with high sensitivity paired with
the ability to isolate and activate precursor
ions of interest in the gas-phase without the
need for high sample purity. Knowledge on
the dissociation behavior of the compound
class of interest is an essential prerequisite
for the reliable interpretation of the
analytical data and, consequently, for the
proper characterization of the biomolecule-
drug adducts.
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Fig. 3. Electron transfer dissociation of doubly and triply charged molybdenocene-DNA adducts.
